Author, Year | Substance | Total number of participants | Migraine induction rate (N) | Aura induction rate (N) | Frequency of aura attacks (range, pr year) |
---|---|---|---|---|---|
aChristiansen et al., 1999 (MA) [21] | GTN | 12 | 6 | 0 | 7 to 50 |
aSances et al., 2004 (MA) [20] | GTN | 22 | 9 | 3 | NA |
aAfridi et al., 2004 (MA) [19] | GTN | 21 | 14 | 1 | NA |
aHansen et al., 2008 (FHM1) [22] | GTN | 8 | 1 | 0 | < 1 to 10 |
aHansen et al., 2010 (FHM) [23] | GTN | 23 | 7 | 4 | NA |
aHansen et al., 2010 (MA) [10] | CGRP | 14 | 8 | 4 | 2 to 24 |
aHansen et al., 2008 (FHM1 and FMH2) [24] | CGRP | 9 | 2 | 0 | < 1 to 10 |
aHansen et al., 2011 (FHM) [25] | CGRP | 11 | 1 | 0 | 2 to 15 |
cAl-Khazali et al., 2023 (MA/MO) | CGRP | 34 | 24 | 13 | 1 to 179 |
bButt et al., 2018 (MA/MO) [15] | Cilostazol | 16 | 12 | 1 | 2 to 12 |
bHougaard et al., 2020 (MA/MO) [17] | Endothelin-1 | 12 | 0 | 0 | 12 to 48 |
bAl-Karagholi et al., 2021 (MA) [18] | Levcromakalim | 17 | 14 | 10 | 6 to 50 |
bButt et al., 2022 (MA/MO) [16] | Sildenafil | 16 | 9 | 3 | 2 to 12 |